Acknowledgement
This research was supported by the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS]; 19am0101101j0003), Basic Science and Platform Technology Program for Innovative Biological Medicine from the Japan Agency for Medical Research and Development (AMED; 15am0301005h0002), Grant from the International Joint Usage/Research Center, the Institute of Medical Science, the University of Tokyo, and a Grant-in-Aid for Scientific Research from KAKENHI (17H03597). We would like to thank Dr. H. Miyoshi (RIKEN BRC) for kindly providing the lentiviral vector encoding CSIV-TRE-RfA-UbC-KT for this study.
References
- Adida, C., Crotty, P.L., McGrath, J., Berrebi, D., Diebold, J., and Altieri, D.C. (1998). Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol. 152, 43-49.
- Bakshi, R., Hassan, M.Q., Pratap, J., Lian, J.B., Montecino, M.A., van Wijnen, A.J., Stein, J.L., Imbalzano, A.N., and Stein, G.S. (2010). The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes. J. Cell. Physiol. 225, 569-576. https://doi.org/10.1002/jcp.22240
- Bando, T. and Sugiyama, H. (2006). Synthesis and biological properties of sequence-specific DNA-alkylating pyrrole-imidazole polyamides. Acc. Chem. Res. 39, 935-944. https://doi.org/10.1021/ar030287f
- Ben-Ami, O., Friedman, D., Leshkowitz, D., Goldenberg, D., Orlovsky, K., Pencovich, N., Lotem, J., Tanay, A., and Groner, Y. (2013). Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. Cell Rep. 4, 1131-1143. https://doi.org/10.1016/j.celrep.2013.08.020
- Brennan, B., De Salvo, G.L., Orbach, D., De Paoli, A., Kelsey, A., Mudry, P., Francotte, N., Van Noesel, M., Bisogno, G., Casanova, M., et al. (2016). Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study-EpSSG NRSTS 2005. Eur. J. Cancer 60, 69-82. https://doi.org/10.1016/j.ejca.2016.02.027
- Brennan, B., Stiller, C., and Bourdeaut, F. (2013). Extracranial rhabdoid tumours: what we have learned so far and future directions. Lancet Oncol. 14, e329-e336. https://doi.org/10.1016/S1470-2045(13)70088-3
- Brennan, B.M., Foot, A.B., Stiller, C., Kelsey, A., Vujanic, G., Grundy, R., Pritchard Jones, K., and United Kingdom Children's Cancer Study Group (UKCCSG) (2004). Where to next with extracranial rhabdoid tumours in children. Eur. J. Cancer 40, 624-626. https://doi.org/10.1016/j.ejca.2003.11.014
- Chang, T.L., Ito, K., Ko, T.K., Liu, Q., Salto-Tellez, M., Yeoh, K.G., Fukamachi, H., and Ito, Y. (2010). Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology 138, 255-265. https://doi.org/10.1053/j.gastro.2009.08.044
- Daifu, T., Mikami, M., Hiramatsu, H., Iwai, A., Umeda, K., Noura, M., Kubota, H., Masuda, T., Furuichi, K., Takasaki, S., et al. (2021). Suppression of malignant rhabdoid tumors through Chb-M'-mediated RUNX1 inhibition. Pediatr. Blood Cancer 68, e28789.
- Goyama, S., Schibler, J., Cunningham, L., Zhang, Y., Rao, Y., Nishimoto, N., Nakagawa, M., Olsson, A., Wunderlich, M., Link, K.A., et al. (2013). Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J. Clin. Invest. 123, 3876-3888. https://doi.org/10.1172/JCI68557
- Hyde, R.K., Zhao, L., Alemu, L., and Liu, P.P. (2015). Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice. Leukemia 29, 1771-1778. https://doi.org/10.1038/leu.2015.58
- Ito, K., Lim, A.C., Salto-Tellez, M., Motoda, L., Osato, M., Chuang, L.S., Lee, C.W., Voon, D.C., Koo, J.K., Wang, H., et al. (2008). RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14, 226-237. https://doi.org/10.1016/j.ccr.2008.08.004
- Ito, Y., Bae, S.C., and Chuang, L.S. (2015). The RUNX family: developmental regulators in cancer. Nat. Rev. Cancer 15, 81-95. https://doi.org/10.1038/nrc3877
- Janes, K.A. (2011). RUNX1 and its understudied role in breast cancer. Cell Cycle 10, 3461-3465.
- Kamikubo, Y. (2018). Genetic compensation of RUNX family transcription factors in leukemia. Cancer Sci. 109, 2358-2363. https://doi.org/10.1111/cas.13664
- Kamikubo, Y., Zhao, L., Wunderlich, M., Corpora, T., Hyde, R.K., Paul, T.A., Kundu, M., Garrett, L., Compton, S., Huang, G., et al. (2010). Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1. Cancer Cell 17, 455-468. https://doi.org/10.1016/j.ccr.2010.03.022
- Kasof, G.M. and Gomes, B.C. (2001). Livin, a novel inhibitor of apoptosis protein family member. J. Biol. Chem. 276, 3238-3246. https://doi.org/10.1074/jbc.M003670200
- Katsumi, Y., Iehara, T., Miyachi, M., Yagyu, S., Tsubai-Shimizu, S., Kikuchi, K., Tamura, S., Kuwahara, Y., Tsuchiya, K., Kuroda, H., et al. (2011). Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochem. Biophys. Res. Commun. 413, 62-68. https://doi.org/10.1016/j.bbrc.2011.08.047
- Kuroda, H., Moritake, H., Sawada, K., Kuwahara, Y., Imoto, I., Inazawa, J., and Sugimoto, T. (2005). Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1 and p16. Cancer Genet. Cytogenet. 158, 172-179. https://doi.org/10.1016/j.cancergencyto.2004.08.032
- Kuwahara, Y., Wei, D., Durand, J., and Weissman, B.E. (2013). SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters. Mol. Cancer Res. 11, 251-260. https://doi.org/10.1158/1541-7786.MCR-12-0390
- LaCasse, E.C., Baird, S., Korneluk, R.G., and MacKenzie, A.E. (1998). The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17, 3247-3259. https://doi.org/10.1038/sj/onc/1202569
- Lim, M., Zhong, C., Yang, S., Bell, A.M., Cohen, M.B., and Roy-Burman, P. (2010). Runx2 regulates survivin expression in prostate cancer cells. Lab Invest. 90, 222-233.
- Minoshima, M., Bando, T., Shinohara, K., and Sugiyama, H. (2009). Molecular design of sequence specific DNA alkylating agents. Nucleic Acids Symp. Ser. (Oxf.) (53), 69-70.
- Misawa, A., Hosoi, H., Imoto, I., Iehara, T., Sugimoto, T., and Inazawa, J. (2004). Translocation (1;22)(p36;q11.2) with concurrent del(22)(q11.2) resulted in homozygous deletion of SNF5/INI1 in a newly established cell line derived from extrarenal rhabdoid tumor. J. Hum. Genet. 49, 586-589. https://doi.org/10.1007/s10038-004-0191-y
- Mitsuda, Y., Morita, K., Kashiwazaki, G., Taniguchi, J., Bando, T., Obara, M., Hirata, M., Kataoka, T.R., Muto, M., Kaneda, Y., et al. (2018). RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells. Sci. Rep. 8, 6423.
- Morita, K., Maeda, S., Suzuki, K., Kiyose, H., Taniguchi, J., Liu, P.P., Sugiyama, H., Adachi, S., and Kamikubo, Y. (2017b). Paradoxical enhancement of leukemogenesis in acute myeloid leukemia with moderately attenuated RUNX1 expressions. Blood Adv. 1, 1440-1451. https://doi.org/10.1182/bloodadvances.2017007591
- Morita, K., Noura, M., Tokushige, C., Maeda, S., Kiyose, H., Kashiwazaki, G., Taniguchi, J., Bando, T., Yoshida, K., Ozaki, T., et al. (2017c). Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells. Sci. Rep. 7, 16604.
- Morita, K., Suzuki, K., Maeda, S., Matsuo, A., Mitsuda, Y., Tokushige, C., Kashiwazaki, G., Taniguchi, J., Maeda, R., Noura, M., et al. (2017a). Genetic regulation of the RUNX transcription factor family has antitumor effects. J. Clin. Invest. 127, 2815-2828. https://doi.org/10.1172/JCI91788
- Morita, K., Tokushige, C., Maeda, S., Kiyose, H., Noura, M., Iwai, A., Yamada, M., Kashiwazaki, G., Taniguchi, J., Bando, T., et al. (2018). RUNX transcription factors potentially control E-selectin expression in the bone marrow vascular niche in mice. Blood Adv. 2, 509-515. https://doi.org/10.1182/bloodadvances.2017009324
- Nakahara, T., Kita, A., Yamanaka, K., Mori, M., Amino, N., Takeuchi, M., Tominaga, F., Hatakeyama, S., Kinoyama, I., Matsuhisa, A., et al. (2007). YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 67, 8014-8021. https://doi.org/10.1158/0008-5472.CAN-07-1343
- Rothe, M., Pan, M.G., Henzel, W.J., Ayres, T.M., and Goeddel, D.V. (1995). The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83, 1243-1252. https://doi.org/10.1016/0092-8674(95)90149-3
- Sood, R., Kamikubo, Y., and Liu, P. (2017). Role of RUNX1 in hematological malignancies. Blood 129, 2070-2082. https://doi.org/10.1182/blood-2016-10-687830
- Tomlinson, G.E., Breslow, N.E., Dome, J., Guthrie, K.A., Norkool, P., Li, S., Thomas, P.R., Perlman, E., Beckwith, J.B., D'Angio, G.J., et al. (2005). Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factor. J. Clin. Oncol. 23, 7641-7645. https://doi.org/10.1200/JCO.2004.00.8110
- Wang, X., Sansam, C.G., Thom, C.S., Metzger, D., Evans, J.A., Nguyen, P.T., and Roberts, C.W. (2009). Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Res. 69, 8094-8101. https://doi.org/10.1158/0008-5472.CAN-09-0733
- Weissmiller, A.M., Wang, J., Lorey, S.L., Howard, G.C., Martinez, E., Liu, Q., and Tansey, W.P. (2019). Inhibition of MYC by the SMARCB1 tumor suppressor. Nat. Commun. 10, 2014.